Ticagrelor Concept

subject area of

• A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction  Academic Article
• A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes  Academic Article
• Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers  Academic Article
• Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers  Academic Article
• Antiplatelet Therapy and Cardiac Surgery: Review of Recent Evidence and Clinical Implications  Academic Article
• Antithrombotic drug removal from whole blood using Haemoadsorption with a porous polymer bead sorbent  Academic Article
• Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (COAPT)  Academic Article
• Contemporary Management of ST-Elevation Myocardial Infarction  Academic Article
• Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor  Academic Article
• Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention  Academic Article
• Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI  Academic Article
• Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy  Academic Article
• Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes  Academic Article
• In ACS with planned invasive evaluation, prasugrel vs ticagrelor reduced a composite of death, MI, or stroke at 1 y  Academic Article
• In Vitro Reversal of the Anti-Aggregant Effect of Ticagrelor Using Untreated Platelets  Academic Article
• In stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding  Academic Article
• Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI  Academic Article
• Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian Observational AntiPlatelet sTudy  Academic Article
• New antithrombotic agents—insights from clinical trials  Academic Article
• Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial  Academic Article
• Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future  Academic Article
• Platelet Transfusion for Ticagrelor Reversal  Academic Article
• Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study  Academic Article
• Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies  Academic Article
• Reversal of the antiplatelet effect of ticagrelor by simulated platelet transfusion  Academic Article
• Role of phenotypic and genetic testing in managing clopidogrel therapy  Academic Article
• The Value of Large Randomized Trials of Two Active Interventions to Define the Optimal Treatment in Patients With Acute Coronary Syndrome  Academic Article
• There seems to be a low risk of experiencing postoperative bleeding in patients undergoing dental extractions or minor oral surgery who continue using antiplatelet therapy  Academic Article
• Ticagrelor versus clopidogrel in real-world patients with ST elevation myocardial infarction: 1-year results by propensity score analysis  Academic Article
• Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study  Academic Article